XNPT stopped heart burn drug trial:PPS is $5.92 now!
XenoPort to stop development of heartburn drug
Related News
* UPDATE 1-Gene therapy shows promise for Parkinson's
Wed, Mar 16 2011
* UPDATE 2-Novartis sees blood cancer drug as blockbuster
Tue, Mar 15 2011
* UPDATE 3-Dendreon gets FDA OK to quadruple Provenge capacity
Thu, Mar 10 2011
* New lupus drug may end treatment nightmare for some
Thu, Mar 10 2011
XenoPort Inc
XNPT.O
$5.89
-0.78-11.69%
12:28pm EST
AstraZeneca PLC
AZN.L
2,853.00p
+25.00+0.88%
12:29pm EST
Glaxosmithkline Plc
GSK.L
1,153.50p
+11.50+1.01%
12:29pm EST
Mon Mar 21, 2011 9:21am EDT
(Reuters) - XenoPort Inc (XNPT.O) will stop development of its experimental drug to treat heartburn after it failed to meet the main goal of a mid-stage trial, sending its shares down 12 percent in pre-market trading.
The company was developing the drug, arbaclofen placarbil, as a combination therapy for people who suffer from gastroesophageal reflux disease (GERD), but do not get complete relief from the medicines that doctors currently prescribe to treat it.
A class of drugs called proton pump inhibitors, or PPIs, such as AstraZeneca's (AZN.L) Nexium and Prilosec are the current standard of care for patients with GERD.
News 
Market Data 
Discover 
